CM Fadnavis urges universities to lead cancer research
Synopsis
Key Takeaways
At a convocation stage in Wardha, Maharashtra Chief Minister Devendra Fadnavis sent a pointed message to India's higher education community on Saturday, 17 October 2026: universities cannot stay on the sidelines of the country's fight against cancer. Speaking at the 17th Ceremonial Convocation 2026 of the Adani Institute of Higher Education and Research, Fadnavis called on academic institutions to actively drive innovation in oncology through research and drug discovery.
Addressing graduates and faculty, the Chief Minister urged, 'Universities must drive innovation in cancer treatment through research and drug discovery' — a call he reinforced in Marathi: 'कर्करोगावरील उपचारांसाठी संशोधन आणि औषधनिर्मितीतील नव्या शोधांच्या माध्यमातून विद्यापीठांनी नवसंशोधनाला चालना दिली पाहिजे' ('Universities must drive new research through discoveries in research and drug production for cancer treatment').
Why Wardha's convocation stage became a health-policy moment
The Adani Institute of Higher Education and Research, based in Wardha in eastern Maharashtra, sits in a region historically associated with medical education and social welfare institutions. Fadnavis's choice to use a convocation address — a moment aimed squarely at the next generation of researchers — to spotlight cancer treatment underlines how urgently state leadership wants academia to move from classroom to lab bench to clinic.
The push aligns with the National Education Policy 2020, which explicitly called on higher education institutions to strengthen research and innovation ecosystems, including in health sciences. Indian state governments have increasingly encouraged universities to contribute to domestic drug discovery and oncology research as part of broader pharmaceutical self-reliance goals. Maharashtra has been positioning its higher education sector to build those bridges between academia and healthcare needs.
The gap CM Fadnavis wants universities to close
Cancer remains one of India's most pressing public health burdens, with demand for affordable, domestically developed treatments growing year on year. Yet the pipeline from university research to actual drug development has historically been thin. Fadnavis's call is a direct challenge to institutions: the talent graduating in these halls must turn toward solving problems that affect millions of patients. The stakes are tangible, not abstract.
Whether the address translates into concrete state funding commitments or formal university-industry partnerships for oncology research will be the measure of its impact — and Maharashtra's education and health departments will be watched closely for follow-through.